Skip to main content
Premium Trial:

Request an Annual Quote

Recent RNAi-Related Deals with Big Pharma

Premium
In the roughly seven years since Science declared RNA interference as its breakthrough of the year, the biopharmaceutical industry has warmed up significantly to the therapeutic potential of the gene-silencing technology. Most recently, GlaxoSmithKline struck a deal to collaborate with Regulus Therapeutics to develop microRNA-targeting drugs.
Click here for an overview of the biggest tie-ups between RNAi and microRA drug developers and big pharma/biotech.